INTRODUCTION {#s1}
============

Whole-genome and exome sequencing efforts are increasingly identifying genetic variation in the general human population as well as candidate genetic variants associated with disease ([@DMM035972C44]; [@DMM035972C86]). There are several approaches for predicting and testing the pathogenicity of a genetic variant ([@DMM035972C17]; [@DMM035972C63]; [@DMM035972C74]). However, demonstrating a function of a particular sequence variant remains challenging. Genome editing now allows for the precise engineering of human genetic variants in animal models for rigorous functional testing ([@DMM035972C21]; [@DMM035972C60]). There are examples of the use of CRISPR-Cas9 engineering in mouse and *Caenorhabditis* *elegans* animal models to demonstrate functional effects of human disease-associated sequence variants ([@DMM035972C2]; [@DMM035972C20]; [@DMM035972C46]; [@DMM035972C62]). However, it is not yet clear how effectively human variants of unknown significance can be functionally tested through genome editing in animal models.

Congenital heart defects (CHDs) are a prominent example of a human disorder with complex genetics ([@DMM035972C24]; [@DMM035972C29]; [@DMM035972C89]). CHDs occur in ∼1% of live births and are the leading cause of infant death owing to birth defects. Intensive studies have uncovered prominent roles for transcription and chromatin factors in heart development and CHDs ([@DMM035972C11]; [@DMM035972C24]; [@DMM035972C29]). Cardiac transcription factors of the GATA, HAND, MEF2, NKX, SRF and TBX families are required for heart development in mouse and zebrafish animal models, and mutations in genes encoding these factors can cause human CHDs ([@DMM035972C23]; [@DMM035972C52]; [@DMM035972C58]). Large-scale whole-exome sequencing studies find that CHD cases show an excess of *de novo* mutations for many transcription and chromatin factors ([@DMM035972C34]; [@DMM035972C90]). In spite of these efforts, these *de novo* mutations likely account for only ∼10% of CHDs ([@DMM035972C29]; [@DMM035972C34]; [@DMM035972C90]). Although additional studies are identifying potential contributions of inherited mutations in CHDs ([@DMM035972C42]), our understanding of the genetics of CHDs is still incomplete.

The genetics of CHDs is complex, in part, because the same candidate gene, and even the same sequence variant, can be associated with a spectrum of heart malformations and can even be present in control cases ([@DMM035972C24]; [@DMM035972C29]; [@DMM035972C89]). This is exemplified in studies of *NKX2.5* mutations in CHD patients and families ([@DMM035972C22]; [@DMM035972C53]; [@DMM035972C72]). Thus, genetic risk factors, or modifier genes, likely influence the phenotype of CHDs, but modifier genes are difficult to identify and characterize ([@DMM035972C24]; [@DMM035972C29]; [@DMM035972C89]). In order to understand the etiology of CHDs and the roles of genetic risk factors in influencing the phenotypic spectrum of CHDs, it is imperative that we increase our understanding of how genetic variants and modifier alleles regulate heart development and contribute to CHDs.

Sequence variants in human PBX genes have been identified in patients with CHDs ([@DMM035972C3]; [@DMM035972C70]), indicating that these PBX variants could contribute to CHDs. One of these variants, an inherited missense variant in the coding region of the *PBX3* gene (p.A136V; 9:128678097 C\>T), occurred at a frequency of 2.6% in a cohort of CHD patients (0.66% in controls; [@DMM035972C3]). These patients exhibited a spectrum of CHDs, particularly outflow tract malformations ([@DMM035972C3]). Pbx genes encode three-amino-acid loop extension (TALE)-class homeodomain-containing DNA-binding proteins, which have diverse roles in development and disease ([@DMM035972C10]; [@DMM035972C56]). In mouse embryos, *Pbx1* is required for heart development, and loss of different combinations of null alleles of *Pbx1*, *Pbx2* and *Pbx3* leads to a spectrum of cardiac outflow tract defects ([@DMM035972C12]; [@DMM035972C73]). Our previous studies have shown that zebrafish Pbx proteins are also needed for outflow tract development, and for early myocardial differentiation and morphogenesis ([@DMM035972C43]; [@DMM035972C51]). The *PBX3* p.A136V variant lies in a highly conserved polyalanine tract, which has been implicated in Pbx binding to histone deacetylase (HDAC) chromatin proteins ([@DMM035972C65]). Although *in silico* programs predict this variant to be deleterious ([@DMM035972C3]), it is not known whether it affects the function of *PBX3* or contributes to CHD. Because this variant is present in controls and has the potential to be inherited, it might represent a modifier or risk factor for CHDs. The *PBX3* p.A131V variant is present in the human population with an allele frequency of \>0.6% \[[@DMM035972C3]; Exome Aggregation Consortium (ExAC), <http://exac.broadinstitute.org/>\], and so it is likely to be excluded from studies of *de novo* or rare inherited variants associated with CHDs ([@DMM035972C34]; [@DMM035972C42]; [@DMM035972C69]; [@DMM035972C90]).

Here, we use CRISPR-Cas9 genome editing in zebrafish to test whether the *PBX3* p.A131V variant can function as a modifier allele in CHDs. In particular, we test whether this variant enhances the phenotype caused by loss of a cardiac specification factor, Hand2, in zebrafish heart development. Our study is the first example, of which we are aware, of using precision genome editing in zebrafish to demonstrate a function for a human disease-associated single nucleotide variant of unknown significance. Our work provides a proof of principle for using genome editing in zebrafish to test the functions of human DNA variants in complex genetic disease. Our work also underscores the importance of testing the roles of inherited variants as genetic modifiers of CHDs.

RESULTS {#s2}
=======

Zebrafish *pbx4*, but not *pbx3b*, is required for early cardiac morphogenesis {#s2a}
------------------------------------------------------------------------------

An inherited heterozygous variant in *PBX3*, c.407 C\>T, predicting p.Arg136\>Val, was previously identified as enriched in a cohort of patients with CHDs ([@DMM035972C3]). The allelic frequency of this variant was significantly less frequent in the study\'s control population (*P*=0.047; [@DMM035972C3]), and is also significantly less frequent in the current ExAC database population (*P*=0.0047, Chi-square test; ExAC, <http://exac.broadinstitute.org/>). This *PBX3* p.A136V variant is present in a highly conserved polyalanine tract, which lies between the two PBC domains that interact with HDAC and Meis proteins ([Fig. 1](#DMM035972F1){ref-type="fig"}A; [@DMM035972C15]; [@DMM035972C65]). The human and zebrafish Pbx genes that do not show 100% conservation of the polyalanine tract (human *PBX4* and zebrafish *pbx2* and *pbx3a*; [Fig. 1](#DMM035972F1){ref-type="fig"}A) appear to have reduced functional roles in development, as human *PBX4* variants in the general population are observed at about the same frequencies as expected by chance (ExAC, <http://exac.broadinstitute.org/>), and zebrafish *pbx2* null mutants are homozygous viable as adults (G.H.F. and L.M., unpublished). However, loss-of-function variants in *PBX3* are highly underrepresented in the ExAC database, suggesting that human *PBX3* is required for viability. The enrichment of the *PBX3* p.A136V variant in a CHD patient cohort suggests that it might contribute a modifier role in the complex genetics of CHDs, and led us to investigate a potential function of this allele in zebrafish. Fig. 1.**Zebrafish *pbx4*, but not *pbx3b*, is required for early cardiac morphogenesis.** (A) Alignment of human (Hs) and zebrafish (Dr) Pbx proteins in the region of the polyalanine tract. Numbers indicate amino acid positions. Partial PBC-A and PBC-B domains are underlined. The arrow marks the position of amino acid 136 in human PBX3. (B) Phylogenetic analysis of human (Hs), mouse (Mm) and zebrafish (Dr) Pbx genes. DmExd is the *Drosophila* Pbx gene ortholog *extradenticle*. (C) qRT-PCR analysis of Pbx gene expression in wild-type zebrafish embryos at four embryonic stages: eight-cell (∼1.25 hpf), 14 somites (s; ∼16 hpf), 24 hpf and 48 hpf. Levels of expression of each Pbx gene are shown relative to the expression of *odc1*. Error bars represent standard deviations for three technical replicates. (D) Schematic of zebrafish Pbx3b protein domains and inferred domains encoded by the CRISPR-Cas9-generated *pbx3b^scm8^* allele. (E) Images of live *pbx3b^scm8/+^* and *pbx3b^scm8/scm8^* larvae at 5 dpf. *pbx3b^scm8/scm8^* larvae show no obvious heart or other defects at least up to 7 dpf (*n*=15, *pbx3b^scm8/scm8^*; *n*=14, *pbx3b^scm8/+^*; *n*=7, *pbx3b^+/+^*). Scale bar: 300 μm. (F) qRT-PCR analysis of Pbx gene expression in *pbx3b^scm8/scm8^* embryos relative to sibling *pbx3b^+/+^* embryos at 48 hpf. Levels of expression of each Pbx gene are normalized to the expression of *eef1a1l1*. Error bars represent standard deviations for four biological replicates. \**P*=0.0005, Student\'s *t*-test using Welch\'s correction for unequal standard deviations. (G) Western blot analysis of Pbx protein expression. *pbx3^scm8/scm8^* and *pbx4^b557/b557^* embryos were used to document identities of the proteins recognized by the anti-pan-Pbx antibody. The upper band is Pbx2, as previously described ([@DMM035972C50]; [@DMM035972C84]; G.H.F. and L.M., unpublished). Quantification of the middle band, normalized to Actin levels, shows that *pbx3^scm8/scm8^* embryos have 65% of wild-type levels, *pbx4^b557/b557^* embryos have 54% of wild-type levels and *pbx3^scm8/scm8^;pbx4^b557/b557^* embryos have 10% of wild-type levels, demonstrating that the middle band consists of both Pbx3b and Pbx4. (H) Myocardial marker *myl7* expression at 24 hpf appears normal in *pbx3^+/+^;pbx4^+/+^* (*n*=11), *pbx3^scm8/scm8^;pbx4^+/+^* (*n*=2) and *pbx3^scm8/scm8^;pbx4^b557/+^* (*n*=15) embryos. *pbx3^+/+^;pbx4^b557/b557^* (*n*=8) and *pbx3^scm8/scm8^;pbx4^b557/b557^* (*n*=7) embryos show similarly disrupted early heart tube morphogenesis, as we previously described for *pbx4^b557/b557^* embryos ([@DMM035972C43]). Dorsal views; anterior is up. Scale bar: 50 μm. (I) Expression of myocardial marker *myl7* (red) and outflow tract marker *elnb* (green) ([@DMM035972C54]) at 60 hpf appears normal in *pbx3^+/+^;pbx4^+/+^* (*n*=8) and in *pbx3^scm8/scm8^;pbx4^+/+^* (*n*=9) embryos. *pbx3^+/+^;pbx4^b557/b557^* (*n*=11) and *pbx3^scm8/scm8^;pbx4^b557/b557^* (*n*=10) embryos show variably disrupted myocardial and outflow tract morphogenesis, similar to what we previously described for *pbx4^b557/b557^* embryos ([@DMM035972C43]). V, ventricle; A, atrium. Ventral views; anterior is up. Scale bar: 50 μm.

In zebrafish and in mice, multiple Pbx genes are expressed broadly and have high functional redundancy ([@DMM035972C8]; [@DMM035972C26]; [@DMM035972C56]; [@DMM035972C61]; [@DMM035972C64]). Zebrafish have six Pbx genes, and *pbx3b* is the closest ortholog of human *PBX3* ([Fig. 1](#DMM035972F1){ref-type="fig"}B). Neither *pbx3b* nor *pbx3a* are detectably expressed during early zebrafish development prior to ∼48 h postfertilization (hpf) ([Fig. 1](#DMM035972F1){ref-type="fig"}C; [@DMM035972C64]; [@DMM035972C84]). Because *pbx3b* has a conserved polyalanine tract ([Fig. 1](#DMM035972F1){ref-type="fig"}A) and shows upregulated expression by 48 hpf ([Fig. 1](#DMM035972F1){ref-type="fig"}C) (after heart tube formation in zebrafish but around the stage of early outflow tract development) ([@DMM035972C31]), we tested the function of *pbx3b* using CRISPR-Cas9 to generate zebrafish *pbx3b* mutants. The *pbx3b^scm8^* mutation that we generated creates an early stop codon ([Fig. 1](#DMM035972F1){ref-type="fig"}D). We found that zebrafish *pbx3b^scm8/scm8^* larvae are viable and appear normal ([Fig. 1](#DMM035972F1){ref-type="fig"}E). We confirmed that the *pbx3b^scm8^* mutation leads to downregulation of *pbx3b* expression in *pbx3b^scm8/scm8^* embryos, likely due to nonsense-mediated RNA degradation, as observed for *pbx4* in *pbx4^b557/b557^* embryos ([@DMM035972C61]). We did not observe any upregulation of other Pbx genes that could compensate for loss of *pbx3b* ([Fig. 1](#DMM035972F1){ref-type="fig"}F). We also determined that *pbx3b^scm8/scm8^* embryos show reduced levels of Pbx3b protein but, again, show no evidence for upregulation of other Pbx proteins ([Fig. 1](#DMM035972F1){ref-type="fig"}G). *pbx3b* does not show any detectable requirements during early heart development, as heart tube formation, heart chamber formation and outflow tract development appear grossly normal in *pbx3b^scm8/scm8^* embryos ([Fig. 1](#DMM035972F1){ref-type="fig"}F,G). *pbx4*, however, is the main zebrafish Pbx gene expressed during early zebrafish development ([Fig. 1](#DMM035972F1){ref-type="fig"}C; [@DMM035972C84]). We have previously shown that zebrafish *pbx4* is needed for proper heart and outflow tract development ([@DMM035972C43]; [@DMM035972C51]). In particular, *pbx4* mutant embryos show disrupted myocardial morphogenesis and variable defects in outflow tract development ([@DMM035972C43]; [Fig. 1](#DMM035972F1){ref-type="fig"}F,G). Because Pbx genes have been shown to function redundantly ([@DMM035972C8]; [@DMM035972C26]; [@DMM035972C50]; [@DMM035972C84]), we tested whether *pbx3b* and *pbx4* function redundantly during early myocardial morphogenesis and outflow tract development. We crossed our *pbx3b^scm8^* strain with the *pbx4^b557^* null allele strain ([@DMM035972C43]; [@DMM035972C61]) to generate *pbx3b^scm8/scm8^;pbx4^b557/b557^* embryos. *pbx4^b557/b557^* and *pbx3b^scm8/scm8^;pbx4^b557/b557^* embryos both show variably disrupted formation of the myocardium and outflow tract ([Fig. 1](#DMM035972F1){ref-type="fig"}F,G), but *pbx3b^scm8/scm8^;pbx4^b557/b557^* embryos do not appear to exhibit any more severe myocardial differentiation and outflow tract defects than those that we previously described for *pbx4^b557/b557^* embryos ([Fig. 1](#DMM035972F1){ref-type="fig"}F,G; [@DMM035972C43]). Thus, in zebrafish, *pbx4*, but not *pbx3b*, plays a critical function in early myocardial and outflow tract formation. Studies of gene expression in early human embryos find that *PBX3* is expressed at higher levels than other PBX genes ([@DMM035972C87]), similar to *pbx4* in zebrafish ([Fig. 1](#DMM035972F1){ref-type="fig"}C). Functional differences between Pbx genes have been argued to be more likely caused by differences in expression than differences in biochemical activity ([@DMM035972C56]; [@DMM035972C61]). Therefore, we decided to address the function of the human *PBX3* p.A136V variant in the zebrafish *pbx4* gene.

Engineering zebrafish *pbx4* p.A131V variant strains {#s2b}
----------------------------------------------------

Compared with the human *PBX3* p.A136 site, the zebrafish *pbx4* gene has an orthologous site of A131 (nucleotide C392; [Figs 1](#DMM035972F1){ref-type="fig"}A and [2](#DMM035972F2){ref-type="fig"}A). To engineer zebrafish carrying the *pbx4* p.A131V variant, we turned to the CRISPR-Cas9 system ([@DMM035972C5]; [@DMM035972C38], [@DMM035972C40]). Although there have been recent improvements, most studies report a low efficiency of introducing precise base changes using CRISPR-Cas9 in zebrafish ([@DMM035972C35]; [@DMM035972C67]; [@DMM035972C92], [@DMM035972C93]). Therefore, to optimize our efforts, we first wanted to ensure that we were using efficient CRISPR-component reagents. Fig. 2.**CRISPR engineering enables the generation of a zebrafish *pbx4* p.A131V variant strain.** (A) Schematic of zebrafish Pbx4 protein domains. HD, homeodomain; PBC A/B, conserved Pbx domains. The asterisk indicates the polyalanine tract. (B) *pbx4* locus for targeting the *pbx4 C392/A131* site. The \*C nucleotide is nucleotide 392 in the A131 codon. Two adjacent PAM sequences (TGG and AGG) are underlined and the target site for sgRNA-3 is in uppercase. Surrounding sequence is in lowercase. (C) *pbx4* guide RNAs tested. The middle column shows the genomic region for each guide RNA. The target site is in uppercase. The PAM is in bold underlined uppercase. Surrounding sequence is in lowercase. The right column shows the sequence of the variable region of the sgRNA produced after transcription from pDR274, which begins with a 5′ GG dinucleotide. A red 'G' indicates a mismatch with the genomic sequence; a green 'G' indicates a match. (D) DNA restriction fragment length polymorphism (RFLP) analysis of the *pbx4* target region after injection of sgRNA-2 or sgRNA-3. The wild-type PCR amplicon is 684 bp and is cleaved to 241 bp and 443 bp fragments by *Pst*I. Embryos were injected with either a low dose (300 pg *Cas9*+12.5 pg sgRNA) or a high dose (600 pg *Cas9*+25 pg sgRNA) of RNA. In embryos injected with *Cas9*+sgRNA-2, only background levels of nondigested PCR product are present, similar to those seen in noninjected embryos. Injection of *Cas9*+sgRNA-3 results in a large proportion of nondigested PCR product in all embryos assayed (arrow). (E) DNA RFLP analysis of F1 embryos, from CRISPR-Cas9-engineered F0 fish, shows incorporation of the C\>T mutation in one embryo (asterisk), owing to F0 germline mosaicism. Digestion of the PCR product is dependent on the C\>T base change. (F) DNA sequencing chromatogram from heterozygous F1 embryo (asterisk by C) showing precise incorporation of the C\>T change. (G) Wild-type sequence around the *pbx4 C392* site, with the *pbx4* sgRNA target site underlined and C392 highlighted. Sequencing of *scm14* allele shows precise C392T/A131V editing.

We began by designing and testing synthetic guide RNAs. We designed guide RNAs that utilized two adjacent potential protospacer adjacent motif (PAM) sequences (NGG) and overlapped the C392 nucleotide ([Fig. 2](#DMM035972F2){ref-type="fig"}B,C). Synthetic single-guide RNAs (sgRNAs) were produced *in vitro*, as previously described ([@DMM035972C38]), by annealing and ligating pairs of complementary oligonucleotides into a plasmid vector containing a T7 promoter ([Table 1](#DMM035972TB1){ref-type="table"}, [Fig. 2](#DMM035972F2){ref-type="fig"}C). To test the ability of each sgRNA to induce insertions or deletions (indels) at the target locus, we injected one-cell-stage zebrafish embryos with a mixture of *Cas9* mRNA and one of the three sgRNAs, allowed the embryos to develop for 24 h and then collected individual embryos for DNA analysis. Indels were detected by PCR amplifying the region around the target site and digesting the amplicons with *Pst*I, which has a recognition site within the target site ([Fig. 2](#DMM035972F2){ref-type="fig"}B,D). We observed a striking difference in the efficacy of the three sgRNAs. The first two sgRNAs produced no or extremely low levels of indels ([Fig. 2](#DMM035972F2){ref-type="fig"}D and data not shown). In contrast, 24 of 24 embryos assayed after injection of *Cas9*+sgRNA-3 had clearly detectable levels of nondigested PCR product, indicating disruption of the *Pst*I restriction site by CRISPR-induced indels ([Fig. 2](#DMM035972F2){ref-type="fig"}D). Table 1.**Oligonucleotides used for CRISPR-Cas9 mutagenesis and screening**

Next, we designed and tested synthetic single-stranded oligodeoxynucleotide donor templates (ssODNs) for introducing the *pbx4* p.A131V variant through homology directed repair (HDR) ([@DMM035972C40]). We designed five ssODNs for which the sequences overlap the C392 target site and match the genomic sequence, except at the C392 position, where the ssODNs contain a T residue (corresponding to \*C in [Fig. 2](#DMM035972F2){ref-type="fig"}B; ssODNs listed in [Table 1](#DMM035972TB1){ref-type="table"}). At the time this work was being done, there was not a clear consensus regarding the design of oligodeoxynucleotides for HDR, with some studies having success with ssODNs with homology arms in the 18-26 nucleotide range ([@DMM035972C4]; [@DMM035972C39]), and others using ssODNs with homology arms in the 40-49 nucleotide range ([@DMM035972C14]; [@DMM035972C36]). We therefore tested ssODNs with a variety of homology arm lengths. One ssODN had 40 nucleotides matching the genomic sequence on either side of the mismatched T and corresponded to the sense strand (ssODN-1). Two oligodeoxynucleotides had 20-nucleotide homology arms on either side of the base to be changed, with one oligodeoxynucleotide corresponding to the sense strand (ssODN-2) and the other to the antisense strand (ssODN-3). Finally, two oligodeoxynucleotides had 25-nucleotide homology arms and corresponded to the sense (ssODN-4) and antisense (ssODN-5) strands. We injected zebrafish embryos with *Cas9* mRNA+sgRNA-3+each ssODN, allowed the embryos to develop for 24 h, and then assayed them for the presence of indels (using the *Pst*I digest, as above for the sgRNA assays) and for the introduction of the C\>T change. To detect the specific base change, a derived cleaved amplified polymorphic sequences (dCAPS) assay ([@DMM035972C57]) was designed, such that a new *Acc*I restriction site is created when C392 is changed to a T. Of the five ssODNs tested, two produced detectable levels of the restriction fragment expected from introduction of the C\>T base change in some injected embryos (ssODN-4, 5/12 embryos; ssODN-5, 2/12 embryos). The remaining three oligodeoxynucleotides induced no detectable levels of C\>T base change. None of the ssODNs appeared to affect the frequency of induction of indels, with all injection conditions yielding ∼90% of embryos with some level of indels (similar to that shown in [Fig. 2](#DMM035972F2){ref-type="fig"}D; data not shown).

Based on these results, we then co-injected the *pbx4* guide RNA (sgRNA-3), *Cas9* mRNA and the ssODN-4 oligodeoxynucleotide into one-cell zebrafish embryos and raised these F0 animals to adulthood. We screened a total of 60 adult F0 fish for those transmitting germline *pbx4* p.A131V mutations by assaying their F1 embryos at 24 hpf for incorporation of the C392T mutation, using the same PCR and restriction fragment length polymorphism (RFLP) analysis used in screening the ssODNs ([Fig. 2](#DMM035972F2){ref-type="fig"}E). Eleven of 60 F0 fish yielded clutches of F1 embryos positive for the C392T change, irrespective of other indels induced at the *pbx4* locus. From these 11 F0 fish, we observed that a range of one to six out of 12 F1 embryos was positive for the C392T change ([Fig. 2](#DMM035972F2){ref-type="fig"}E), yielding an 8-50% rate (average 14%) of germline transmission of the mutation. For these positive F1 embryos, we sequenced the genomic region around the CRISPR target site and found that two of the 11 F0 fish were transmitting the C392T change alone without any indels in *pbx4* (9/11 had additional indels). Additional F1 embryos from the two F0 fish that were positive for the precise C392T change were then raised to adulthood and screened for the mutation, using the RFLP assay on F1 adult fin biopsies. The genomic region around the CRISPR target site was again sequenced to identify F1 adult fish heterozygous for the precise desired *pbx4* p.A131V variant ([Fig. 2](#DMM035972F2){ref-type="fig"}F,G).

In addition to identifying F0 and F1 fish carrying the precise C392T change, we identified fish carrying a variety of indels at the *pbx4* target site. The mutations we found, consisting of small (1-39 nucleotides) deletions at the target site, are similar to the CRISPR-Cas9-induced indels previously reported in zebrafish ([@DMM035972C13]; [@DMM035972C27]; [@DMM035972C38],[@DMM035972C39]; [@DMM035972C82]). However, out of 13 different indels we identified in F1 fish (from 10 different F0 founders) none were insertions (even in combination with a deletion). In addition, a disproportionate number were in-frame deletions (9/13 indels). As we have only examined in detail the mutations resulting from targeting a single gene with CRISPR-Cas9 and an HDR ssODN, we do not know if the ssODN affected the type of indels produced, or if the indels induced were affected by the particular sgRNA used or by the target site sequence.

With this approach, we identified F1 fish, from two independent F0 founder fish, transmitting the precise C392T change. F1 fish carrying the precise change with no other mutations were then bred to wild-type fish to generate a zebrafish strain, *pbx4^scm14^*, carrying the *pbx4* p.A131V variant ([Fig. 2](#DMM035972F2){ref-type="fig"}G). We sequenced the *pbx4* gene in the *pbx4^scm14^* strain to confirm that there were no other changes introduced in *pbx4* (data not shown).

Upon genotyping adult fish derived from a *pbx4^scm14/+^*×*pbx4^scm14/+^* cross, we obtained the expected frequency of *pbx4^scm14/scm14^* fish (7/32 fish; Chi-square test including all genotypes of the cross, *P*=0.7788), showing that we obtain viable homozygous adults for the *pbx4* p.A131V variant, whereas homozygous null *pbx4^b557/b557^* animals die at ∼5 days postfertilization (dpf) ([@DMM035972C61]). The adult viability suggests that the *pbx4* p.A131V variant does not, on its own, lead to a significant defect in heart development (as we further confirm below).

To test the strength of the *pbx4* p.A131V allele, we crossed the *pbx4^scm14^* strain with the null *pbx4^b557^* strain. From a cross of *pbx4^scm14/+^* fish with *pbx4^b557/+^* fish, we observed that transheterozygous *pbx4^scm14/b557^* fish survive to adulthood and are present at the expected frequency (10/43 fish; Chi-square test including all genotypes of the cross, *P*=0.2640). Thus, this test does not detect any effect of the *pbx4* p.A131V allele. We then used the new *pbx4* variant allele strain to test whether the *pbx4 p.A131V* variant functions as a genetic modifier of other CHD genes.

The *pbx4* p.A131V variant enhances loss of the CHD gene *hand2* {#s2c}
----------------------------------------------------------------

To further test the function of the *pbx4* p.A131V allele, we next wanted to additionally perturb the genetic burden of fish carrying the *pbx4* p.A131V allele. In particular, we decided to directly test whether the *pbx4* p.A131V variant functions as a genetic modifier and enhances the phenotype caused by loss of a known CHD gene, *hand2*. *hand2* encodes a basic helix-loop-helix factor that has critical requirements for embryonic heart development in zebrafish and mice ([@DMM035972C71]; [@DMM035972C88]), and mutations in the human *HAND2* gene have been associated with CHD ([@DMM035972C48]; [@DMM035972C68]; [@DMM035972C77]; [@DMM035972C79]). In zebrafish, *hand2* is required for both cardiomyocyte differentiation and early myocardial morphogenesis ([@DMM035972C28]; [@DMM035972C66]; [@DMM035972C80]; [@DMM035972C88]). Furthermore, our previous work used morpholino knockdowns to show that *hand2* and *pbx4* act together in zebrafish early myocardial morphogenesis ([@DMM035972C51]). We therefore crossed our *pbx4* p.A131V allele strain (*pbx4^scm14^*) with the established null mutant strain, *hand2^s6^* ([@DMM035972C88]). We additionally included the *pbx4^b557^* null allele in these crosses. [Fig. 3](#DMM035972F3){ref-type="fig"}A shows the genetic crosses used to obtain embryos of all possible homozygous and heterozygous mutant combinations needed for our analyses. Fig. 3.**The *pbx4* p.A131V variant enhances myocardial morphogenesis defects caused by loss of *hand2*.** (A) Genetic crosses of zebrafish strains used to obtain embryos for the analyses of *pbx4;hand2* mutant embryos. All adult breeder fish used in crosses 1-3 were 'siblings', derived from the same clutch from a group cross. (B-G) Myocardial marker *myl7* expression at 24 hpf. Dorsal views; anterior is up. Animal numbers for phenotypic classes are provided in [Table 2](#DMM035972TB2){ref-type="table"}. (B) The heart tube appears normal in *pbx4^+/+^;hand2^+/+^* embryos. (C) *pbx4^b557/b557^;hand2^+/+^* embryos have a medial heart cone *myl7* domain. (D) *pbx4*^+/+^*;hand2^s6/s6^* embryos show a crescent-shaped myocardial fusion defect of the *myl7* domains. (E) A similar phenotype is observed in *pbx4^b557/+^;hand2^s6/s6^*. (F,G) The *myl7* fusion defect is more severe in *pbx4^b557/b557^;hand2^s6/s6^* (F) and *pbx4^scm14/b557^;hand2^s6/s6^* (G). (H) Quantitation of fusion defect of *myl7* domains in different genetic combinations. *myl7* distance measurements were made blind to embryo genotypes. The averages for the *myl7* distances among the different genotypes were compared using one-way ANOVA, and *P*-values were corrected for multiple comparisons using Tukey\'s test. The boxes extend from the 25th to 75th percentiles, the whiskers are at the minimum and maximum, and the bar within the box represents the median. (I-N) Myocardial marker *myl7* expression at 60 hpf. In I-J, ventral views; anterior is up. In K-N, anterior views; dorsal is up. Animal numbers for phenotypic classes are provided in [Table 3](#DMM035972TB3){ref-type="table"}. (I) The heart appears normal in *pbx4^+/+^;hand2^+/+^* embryos. V, ventricle; A, atrium. (J) *pbx4^b557/b557^;hand2^+/+^* embryos have dysmorphic hearts with bulges of the ventricular myocardium (arrow). (K) *pbx4*^+/+^*;hand2^s6/s6^* embryos show an abnormally shaped, medial myocardium positioned more caudally between the eyes (asterisks). (L) A similar phenotype is observed in *pbx4^b557/+^;hand2^s6/s6^*. (M,N) More severe *myl7* bilateral domain phenotypes are observed in *pbx4^b557/b557^;hand2^s6/s6^* (M) and *pbx4^scm14/b557^;hand2^s6/s6^* (N) embryos. Scale bars: 50 μm. Table 2**. Genotype-phenotype analysis of *pbx4;hand2* mutant embryos at 24 hpf** Table 3.**Genotype-phenotype analysis of *pbx4;hand2* mutant embryos at 60 hpf**

We first examined early cardiac development in embryos from these crosses at 24 hpf, using RNA *in situ* expression of *myl7* to examine myocardial precursors. For these experiments, embryos from all crosses were genotyped for *pbx4^b557^*, *pbx4^scm14^* and *hand2^s6^*, using tail tissue from post-*in situ-*hybridized embryos as described in the Materials and Methods. At 24 hpf, wild-type embryos have formed a heart tube ([Fig. 3](#DMM035972F3){ref-type="fig"}B; [@DMM035972C75]), and *pbx4^scm14/scm14^* embryos also appear to have a normal heart tube (data not shown). As we previously described, *pbx4^b557/b557^* embryos show an abnormally shaped, medially positioned myocardium ([Fig. 3](#DMM035972F3){ref-type="fig"}C; [@DMM035972C43]), and *hand2^s6/s6^* embryos show reduced, medial, crescent-shaped myocardial domains that have not assembled together properly, with defective fusion of the myocardial precursors at the midline ([Fig. 3](#DMM035972F3){ref-type="fig"}D; [@DMM035972C88]). We quantified the myocardial fusion defects in these embryos by measuring the distance between the *myl7* domains ([Fig. 3](#DMM035972F3){ref-type="fig"}H). The *hand2^s6/s6^* myocardial fusion defect is significantly more severe in *pbx4^b557/b557^;hand2^s6/s6^* embryos, in that the *myl7* domains have greater bilateral separation ([Fig. 3](#DMM035972F3){ref-type="fig"}D,E,H). We found that *pbx4^scm14/b557^;hand2^s6/s6^* embryos also show a more severe effect on myocardial fusion than that seen in *hand2^s6/s6^* embryos, and, critically, the defect is also more severe than that seen in *pbx4^b557/+^;hand2^s6/s6^* embryos, or in *pbx4^scm14/scm14^;hand2^s6/s6^* embryos ([Fig. 3](#DMM035972F3){ref-type="fig"}D-H). These results show that the *pbx4* p.A131V variant, combined with a null *pbx4* allele, increases the severity of, or enhances, the early myocardial morphogenesis phenotype caused by loss of *hand2* function. We analyzed the frequencies of the myocardial phenotypes in embryos from these crosses ([Table 2](#DMM035972TB2){ref-type="table"}). We classified embryos as having a wild-type heart tube, a medial heart cone (the *pbx4^b557/b557^* phenotype), a medial crescent (the *hand2^s6/s6^* phenotype) or a bilateral domain phenotype (the *pbx4^b557/b557^;hand2^s6/s6^* phenotype). This analysis also shows that the myocardial fusion defect is more severe in *pbx4^scm14/b557^;hand2^s6/s6^* embryos than in *hand2^s6/s6^* embryos, *pbx4^b557/+^;hand2^s6/s6^* embryos or *pbx4^scm14/scm14^;hand2^s6/s6^* embryos ([Table 2](#DMM035972TB2){ref-type="table"}).

We then examined cardiac morphogenesis in embryos from these crosses at 60 hpf, again using RNA *in situ* expression of *myl7*. As above, post-*in situ-*hybridized embryos from all crosses were genotyped for *pbx4^b557^*, *pbx4^scm14^* and *hand2^s6^*. At 60 hpf, wild-type embryos have formed both cardiac chambers ([Fig. 3](#DMM035972F3){ref-type="fig"}I; [@DMM035972C75]), and *pbx4^scm14/scm14^* embryos similarly show normal cardiac morphology (data not shown). As we previously described, *pbx4^b557/b557^* embryos show an abnormally shaped myocardium with bulges of the ventricle ([Fig. 3](#DMM035972F3){ref-type="fig"}J; [@DMM035972C43]). *hand2^s6/s6^* embryos also show an abnormally shaped, medial myocardium that is positioned more caudally ([Fig. 3](#DMM035972F3){ref-type="fig"}K). In *pbx4^b557/b557^;hand2^s6/s6^* embryos, the *myl7* domains are bilaterally separated, as at 24 hpf ([Fig. 3](#DMM035972F3){ref-type="fig"}L). We analyzed the frequencies of these 60 hpf myocardial phenotypes in embryos from all genotypes, classifying embryos as having a wild-type heart, a dysmorphic ventricle (the *pbx4^b557/b557^* phenotype), a medial/caudal myocardium (the *hand2^s6/s6^* phenotype) or a bilateral domain phenotype (the *pbx4^b557/b557^;hand2^s6/s6^* phenotype; [Table 3](#DMM035972TB3){ref-type="table"}). We found that *pbx4^scm14/b557^;hand2^s6/s6^* embryos show a more severe myocardial morphogenesis phenotype than that seen in *hand2^s6/s6^* embryos, and, as at 24 hpf, the defects are more severe than those seen in *pbx4^b557/+^;hand2^s6/s6^* embryos, or in *pbx4^scm14/scm14^;hand2^s6/s6^* embryos. ([Fig. 3](#DMM035972F3){ref-type="fig"}K-N, [Table 3](#DMM035972TB3){ref-type="table"}). These results show that the *pbx4* p.A131V variant, combined with a null *pbx4* allele, increases the severity of, or enhances, the later embryonic myocardial morphogenesis phenotype caused by loss of *hand2* function. We attempted to address whether the *pbx4* p.A131V variant enhanced outflow tract or later-stage cardiac phenotypes of *hand2^s6/s6^* mutants, but we found that *hand2^s6/s6^* mutant embryos lacked expression of the outflow tract marker *elnb* and that *hand2^s6/s6^* mutants showed lethality starting at ∼3 dpf (data not shown), thus precluding these further analyses.

Taken together, these results demonstrate that the *pbx4* p.A131V variant functions as a genetic modifier and enhances the myocardial morphogenesis phenotypes caused by loss of *hand2* function. Therefore, even though the *pbx4 p.A131V* fish are viable and do not have obvious heart defects in an otherwise wild-type genetic background, our results support our hypothesis that the *pbx4 p.A131V* allele can function as a genetic modifier in heart development.

DISCUSSION {#s3}
==========

Here, we used CRISPR-Cas9 precision genome editing to successfully engineer a zebrafish strain with a *PBX3* p.A131V variant of unknown significance that was previously identified in a cohort of patients with CHDs. We engineered the human variant into the homologous *pbx4* p.A131V site in zebrafish. We used the engineered zebrafish to demonstrate that the *pbx4* p.A131V allele acts as a genetic enhancer of the known CHD gene *hand2*. Our work underscores the importance of testing the roles of inherited variants as genetic modifiers of CHDs. Our study is the first example, of which we are aware, of using precision genome editing in zebrafish to demonstrate a function for a human disease-associated variant of unknown significance. Our work helps advance our understanding of the complex genetics of CHDs, and also provides an example of using genome editing in zebrafish to test the causal roles and genetic interactions of human disease-associated DNA variants.

Many approaches in zebrafish and mammalian models have previously been used to characterize the functions of human heart disease-associated DNA sequence variants. One study showed that zebrafish embryos could be used to characterize heart function defects caused by a human sodium channel gene *SCN5A* variant, which is strongly associated with human heart disorders such as arrhythmias ([@DMM035972C37]). However, this study employed overexpression of the human gene in transgenic zebrafish. Zebrafish embryos have often been used to test the functions of potential human disease variants through complementation, in which the orthologous zebrafish gene is typically knocked out through genetic mutation or knocked down with antisense morpholinos, and then mRNA injections of a human wild-type or mutant form are used to attempt rescue of a phenotype ([@DMM035972C19]). However, owing to the inherent transient and mosaic nature of the mRNA injection and overexpression approach, these complementation assays have challenges for examining genetic interactions. A CHD-associated *GATA4* variant has been functionally characterized in a mouse model ([@DMM035972C55]), but this was done with conventional embryonic stem cell targeting, which incorporates a targeting vector into the genome. This same *GATA4* variant was also functionally characterized in patient-derived cardiomyocytes induced from pluripotent stem cells, and this analysis provided a deep, systems-level mechanistic understanding of how this particular variant disrupts cardiomyocyte gene expression and function ([@DMM035972C1]). However, such cell culture models also have challenges for examining genetic interactions and might not reveal the full effects of a variant on a gene\'s function *in vivo*.

Although the development of CRISPR-Cas9 technology has made possible the creation of targeted single-nucleotide changes in zebrafish, the process is still inefficient. Our studies support optimization of the component reagents for successful single-nucleotide editing. We found that different sgRNAs and ssODNs had very different efficacies. Of the three sgRNAs tested, two failed to induce indels at a level we could detect with an RFLP assay, whereas the third resulted in readily detectable indels in nearly all injected embryos. The highly effective sgRNA has a 20-nucleotide targeting region with a single mismatch at the second position, whereas the ineffective sgRNAs had 20-nucleotide targeting regions with two additional mismatched nucleotides at their 5′ ends. Although sgRNAs similar to these (two free Gs 5′ to a 20-nucleotide protospacer) have been used in zebrafish effectively ([@DMM035972C39]), most published studies have used sgRNAs with 20-nucleotide protospacers and no additional 5′ mismatched bases. One- or two-base mismatches at or near the 5′ end of the protospacer have been shown to be tolerated ([@DMM035972C16]; [@DMM035972C27]; [@DMM035972C39]), and a guanine immediately 5′ to the PAM sequence has been shown to correlate positively with indel frequencies ([@DMM035972C25]; [@DMM035972C27]). Thus, the high incidence of indels seen with *pbx4* sgRNA-3 might result from a combination of optimal protospacer length, the presence of only a single mismatch near the 5′ end of the protospacer and a G nucleotide in the final position of the protospacer before the PAM. Less is known about the design of homology-directed repair templates to maximize precise editing, and there is conflicting evidence as to whether ssODNs are more efficient at introducing single-nucleotide changes than long double-stranded DNA repair templates ([@DMM035972C4]; [@DMM035972C6]; [@DMM035972C14]; [@DMM035972C35]; [@DMM035972C36]; [@DMM035972C39]; [@DMM035972C41]; [@DMM035972C45]; [@DMM035972C93]). Previous studies have achieved template-mediated repair using ssODNs of a similar length to, or longer than, our ssODN-4 ([@DMM035972C6]; [@DMM035972C36]; [@DMM035972C39]; [@DMM035972C45]).

Our study provides further support for crucial roles for PBX-related TALE-class homeodomain transcription factors in heart development and CHDs. Pbx1, Pbx2 and Pbx3 proteins and the Pbx-related factor Meis1 all contribute to outflow tract development in mouse embryos ([@DMM035972C12]; [@DMM035972C73]). Zebrafish Pbx and Meis genes are also needed for proper heart development ([@DMM035972C32]; [@DMM035972C43]; [@DMM035972C51]; [@DMM035972C59]). In human cardiomyocyte cell culture models, DNA binding sites for PBX and MEIS factors have been identified as enriched in open chromatin and occurring nearby sites for other cardiac transcription factors ([@DMM035972C33]; [@DMM035972C59]; [@DMM035972C76]; [@DMM035972C83]). Human sequencing studies have found PBX and MEIS gene variants associated with CHDs ([@DMM035972C3]; [@DMM035972C18]; [@DMM035972C47]; [@DMM035972C70]). Notably, a recent study described five patients, each with a CHD and other congenital anomalies, that all had *de novo* missense or nonsense sequence variants in *PBX1* ([@DMM035972C70]). The missense *PBX1* variants occurred in or near the homeodomain and likely affect the transcriptional capabilities of PBX1 ([@DMM035972C70]). The *PBX3* p.A136V variant that we addressed here is in the more N-terminal polyalanine tract, which might bind HDAC proteins ([@DMM035972C65]; [@DMM035972C15]). The polyalanine tract is adjacent to the PBC domains, which interact with Meis and HDAC proteins ([@DMM035972C15]; [@DMM035972C49]; [@DMM035972C65]). Even though one caveat of our study is that we model the human *PBX3* variant in the zebrafish *pbx4* locus, the polyalanine tract is highly conserved in both PBX3 and Pbx4. As future studies identify additional inherited and *de novo* variants in PBX genes associated with CHDs, we will gain a better understanding of which human PBX genes, and which PBX protein domains, are needed for human heart development.

Our study also provides further support for the oligogenic basis of CHDs. Previous studies of Pbx genes in mouse heart development supported a multigenic basis for CHDs ([@DMM035972C73]). Family members carrying the same *HAND2* mutation can exhibit different cardiac defects ([@DMM035972C77]), supporting a role for additional genetic changes influencing the severity of CHDs associated with *HAND2* mutation. In order to reveal a contribution of the *pbx4* p.A131V variant in zebrafish heart development, we had to employ an additional null allele of *pbx4* as well as homozygous loss of *hand2*, conditions that are likely to not be present in human CHD cases. Our efforts underscore the challenges of modeling the functions of human disease-associated genetic variants in animal models. Mutations that are haploinsufficient in humans can often be tolerated when heterozygous in mice ([@DMM035972C9]; [@DMM035972C30]). There are increasing numbers of examples showing that to produce disease-related phenotypic effects of a specific locus in mice or zebrafish animal models, additional or more severe alleles need to be utilized ([@DMM035972C7]; [@DMM035972C9]; [@DMM035972C20]; [@DMM035972C81]; [@DMM035972C91]). For example, human patients homozygous for a variant in *COPB2* exhibited microcephaly, whereas a mouse model required the *Copb2* variant allele to be combined with a *Copb2* null allele to cause brain malformations ([@DMM035972C20]). Furthermore, we do not yet understand the full genetic burden of variants in human CHD cases. A recent study found evidence for rare inherited variants, in genes with a known association with cardiac malformations and in parent-child trios affected by atrioventricular septal defects, and these particular rare variants were generally not observed in control trios ([@DMM035972C95]). This and our study support the idea that inherited variants across multiple genetic loci might contribute to the penetrance and expressivity of CHDs, and provide further support to the oligogenic inheritance of CHDs ([@DMM035972C24]; [@DMM035972C29]).

Forward genetics in mice was used recently to identify an interaction between two genes, *Sap130* and *Pcdha9*, in causing hypoplastic left heart syndrome (HLHS) ([@DMM035972C94]). Intriguingly, this study also identified one human HLHS patient with variants in both *SAP130* and *PCDHA13*, a *Pcdha9* homolog ([@DMM035972C94]). In mice, *Sap130* and *Pcdha9* might work combinatorially, each regulating different pathways important for proper heart development ([@DMM035972C94]). Although we previously described *pbx4* and *hand2* as working together in zebrafish heart development ([@DMM035972C51]), it is possible that they are also working through parallel pathways. Future studies that continue to take advantage of animal models, as well as human genetic sequence data, will further enhance our understanding of the complex genetics of human diseases such as CHD.

MATERIALS AND METHODS {#s4}
=====================

Zebrafish husbandry {#s4a}
-------------------

All experiments involving live zebrafish (*Danio rerio*) were carried out in compliance with Seattle Children\'s Research Institute Institutional Animal Care and Use Committee guidelines. Zebrafish were raised and staged as previously described ([@DMM035972C85]). Staging time refers to hpf at 28.5°C. The wild-type stock and genetic background used was AB. The *pbx4^b557^* mutant strain was previously described and is likely a null allele ([@DMM035972C61]). *pbx4^b557^* genotyping was performed as previously described ([@DMM035972C43]) using forward primer 5′-ACTCGGCGGACTCTCGCAAGC-3′ and reverse primer 5′-GGCTCTCGTCGGTGATGGCCATGATCT-3′ primers. The genotyping PCR product is 128bp; digesting with *Xba*I yields a 98bp product from the mutant allele. In some cases, *pbx4^b557^* animals were genotyped using a KASP assay (LGC Genomics). Reactions were run and fluorescence was measured in a Bio-Rad CFX96, and genotypes were assigned using the Bio-Rad CFX Manager software, according to instructions provided by LGC Genomics. Details for ordering the *pbx4^b557^* KASP assay are available upon request. The *hand2^s6^* mutant strain was previously described and is a deletion of the *hand2* locus ([@DMM035972C88]). For *hand2^s6^* genotyping, we devised a quantitative PCR assay for the number of copies of the *hand2* gene. *hand2* was amplified with forward primer 5′-ACCAAAGCGTACTCCGTCTG-3′ and reverse primer 5′-CAGCGAAGGAATAGCCGTCA-3′. *pbx4* was also amplified as a normalization control using forward primer 5′-GCCGTTAAAACAGCCGTGG-3′ and reverse primer 5′-GTGTTGCTGGAGAGTTTGCC-3′. Reactions were run in duplicate for both genes using the KAPA SYBR FAST kit (KAPA Biosystems KK4600) on a Bio-Rad CFX96 machine. The resulting Ct values were averaged, and a ΔCt was calculated to distinguish *hand2* homozygous, heterozygous and wild-type embryos.

Pbx phylogenetic analysis {#s4b}
-------------------------

Accession numbers for the sequences aligned in [Fig. 1](#DMM035972F1){ref-type="fig"}A are provided in [Table 4](#DMM035972TB4){ref-type="table"}. Sequences were aligned using Clustal Omega ([www.EMBL.org](www.EMBL.org)). The phylogeny was constructed with PhyML using the following settings: Substitution Model LG; Tree Improvement SPR & NNI; Bootstrapping 500 ([www.ATGC-montpellier.fr](www.ATGC-montpellier.fr)). The phylogenetic tree ([Fig. 1](#DMM035972F1){ref-type="fig"}B) was drawn with TreeDyn (<http://phylogeny.lirmm.fr/phylo_cgi/one_task.cgi?task_type=treedyn>). Table 4.**Pbx accession numbers**

Quantitative reverse transcription PCR {#s4c}
--------------------------------------

Total RNA was isolated using TriZol (Ambion; Thermo Fisher Scientific) and reverse-transcribed with a SensiFAST cDNA Synthesis kit (Bioline BIO-65053). Primers were designed using Primer-BLAST such that they either span an intron or one of the pair spans an exon-exon boundary. Primers are listed in [Table 5](#DMM035972TB5){ref-type="table"}. Quantitative reverse transcription PCR (qRT-PCR) was carried out using a KAPA SYBR FAST kit (KAPA Biosystems KK4600) on a Bio-Rad CFX96 machine. For the analysis of Pbx expression levels in wild-type embryos at different stages, Ct values for the zebrafish Pbx genes were corrected for observed primer efficiencies and normalized to *odc1*. For the analysis of Pbx gene expression in *pbx3b^scm8^* mutants, Pbx genes were normalized to *eef1a1l1* and ΔΔCt values were calculated for four wild-type and four mutant replicates, each consisting of pools of eight 48 hpf embryos. *P*-values were calculated with an unpaired Student\'s *t*-test with Welch\'s correction for unequal population standard deviations, using the ΔΔCt values. The graph was constructed by log transforming the ΔΔCt values. Statistical analysis was performed and the box plot was made in GraphPad Prism 7. The boxes extend from the 25th to 75th percentiles, the whiskers are at the minimum and maximum, and the bar within the box represents the median. Table 5.**Oligonucleotides for qRT-PCR**

Generation of mutant zebrafish strains with CRISPR-Cas9 {#s4d}
-------------------------------------------------------

Single-guide constructs were made by annealing pairs of oligonucleotides (listed in [Table 1](#DMM035972TB1){ref-type="table"}) and ligating them into *Bsa*I-digested pDR274 ([@DMM035972C38]). The single-guide plasmids were digested with *Dra*I, and guide RNA was transcribed with the T7 Maxiscript kit (Ambion; Thermo Fisher Scientific). *Cas9* mRNA was made by transcribing *Pme*I-digested pMLM3613 ([@DMM035972C38]) with the T7 Ultra kit (Ambion; Thermo Fisher Scientific). One-cell-stage zebrafish embryos were injected with 600 pg (for *pbx3b*) or 400 pg (for *pbx4*) of *Cas9* mRNA and 25 pg of an sgRNA in a volume of 2 nl. To generate the desired single-nucleotide change in *pbx4*, 50 pg of an ssODN ([Table 1](#DMM035972TB1){ref-type="table"}) was co-injected with *Cas9* mRNA and the sgRNA. Zebrafish were screened for Cas9-generated mutations (insertions or deletions, 'indels') by amplifying with primers flanking the target site (indel assay primers, [Table 1](#DMM035972TB1){ref-type="table"}) followed by a digest to test for loss of a restriction site just upstream of or overlapping the PAM site (*Hpy*AV for *pbx3b*, *Pst*I for *pbx4*). To detect the single-nucleotide change in *pbx4*, a dCAPS assay was designed (<http://helix.wustl.edu/dcaps/>; [@DMM035972C57]) such that PCR amplification of the mutant allele generated an *Acc*I site (*pbx4* dCAPS assay primers in [Table 1](#DMM035972TB1){ref-type="table"}). Mutant alleles were identified in heterozygous F1 or F2 fish by Sanger sequencing and deconvolving the chromatograms with Poly Peak Parser (<http://yosttools.genetics.utah.edu/PolyPeakParser/>).

Immunoblotting {#s4e}
--------------

Embryos were obtained from an incross of *pbx3b^scm8/+^;pbx4^b557/+^* fish. At 48 hpf, tail tips were cut from the embryos and arrayed in 96-well plates for genotyping. The remaining portions of the embryos were arrayed in separate 96-well plates, to which sodium dodecyl sulfate (SDS) sample buffer was added and stored at −20°C until genotyping was completed, at which point the embryo lysates were pooled by genotype. Approximately one embryo equivalent was separated by reducing SDS-polyacrylamide gel electrophoresis and blotted as previously described ([@DMM035972C50]). Blots were probed with anti-pan-Pbx (rabbit serum, 1:500; [@DMM035972C61]) and with anti-Actin as a loading control (1:500; Clone C4, Millipore). The anti-pan-Pbx antibody was raised and validated against multiple zebrafish Pbx proteins ([@DMM035972C50]; [@DMM035972C61]; [@DMM035972C84]). Infrared dye-labeled secondary antibodies (Rockland) were visualized using a LI-COR Odyssey infrared scanner.

Whole-mount RNA *in situ* hybridization and measurement analysis {#s4f}
----------------------------------------------------------------

The following cDNA probes were used: *myl7* ([@DMM035972C96]) and *elnb* ([@DMM035972C54]). Whole-mount *in situ* hybridization colorimetric and fluorescent *in situ* staining was performed as previously described ([@DMM035972C50]; [@DMM035972C78]), with the following modifications. Embryos at 60 hpf were depigmented in 1 part 0.1% KOH (vol.): 1 part 1× PBS-0.1% Tween (vol.): 0.1 part 30% hydrogen peroxide (vol.) for 2 h at room temperature with gentle agitation. Hybridizations for both colorimetric and fluorescent *in situ* experiments were performed in hybridization buffer with 5% dextran sulfate. Following staining, tail clips from post-*in situ-*hybridized embryos were lysed and genotyped for *pbx3b^scm8^*, *pbx4^b557^*, *pbx4^scm14^* and *hand2^s6^*, as above. Imaging was performed on a Leica SP5 confocal microscope with a 40× water immersion objective.

For *myl7* measurements at 24 hpf, we imaged genotyped embryos. Sample sizes were not pre-determined, and no animals were excluded from the analysis. Embryos stained for *myl7* were individually imaged at a consistent magnification on a stereomicroscope. ImageJ (<https://imagej.nih.gov/ij/>) was used to measure the area of *myl7* expression and the distance between bilateral domains of expression, expressed in pixels. The investigator making the measurements was blinded to the sample genotype. For embryos with separate bilateral *myl7* domains, three distance measurements were made for each embryo: between the medial edges of expression at the anterior extent of expression, between the medial edges of expression at the posterior extent of expression, and at the approximate midpoint between the anterior and posterior measurements. These three values were then averaged. For embryos with a single midline domain of *myl7* expression, a distance value of 0 was assigned. For embryos with a crescent-shaped domain, the posterior distance measurement was 0 and the middle and anterior measurements were made as for separate bilateral domains. The averages for the *myl7* distances among the different genotypes were compared using one-way ANOVA, and *P*-values were corrected for multiple comparisons using Tukey\'s test. ANOVA was performed and the box plots were made in GraphPad Prism 7. The boxes extend from the 25th to 75th percentiles, the whiskers are at the minimum and maximum, and the bar within the box represents the median.
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